14 May 2018 - - Suresnes, France-based international pharmaceutical company Servier and R and D-driven specialty pharma Taiho Pharmaceutical Co., Ltd.'s Phase III trial evaluating Lonsurf (trifluridine/tipiracil) plus best supportive care (BSC) versus placebo plus BSC in patients with advanced metastatic gastric cancer met its primary objective to improve overall survival, the company said.
The TAGS trial is a global, randomized, double-blind, placebo-controlled trial evaluating Lonsurf versus placebo in patients with pretreated metastatic gastric cancer. The trial enrolled 507 patients who had received at least two prior regimens for mGC and who were refractory to, or unable to, tolerate further chemotherapy.
Patients were randomized to receive Lonsurf plus best supportive care or placebo plus BSC in order to investigate the efficacy and safety. The primary endpoint is overall survival and secondary endpoint measures include progression free survival, safety and tolerability, as well as quality of life.
Lonsurf is an oral anticancer drug, comprising a combination of trifluridine and tipiracil, whose dual mechanism of action is designed to maintain clinical activity.
Servier, governed by a non-profit foundation, has an international presence in 148 countries and employs 21,000 people worldwide. Entirely independent, the group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development in five areas: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancers and diabetes
Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd. focuses on oncology, allergy and immunology, and urology. the company develops innovative medicines for the treatment of cancer, and in areas other than oncology, the company creates and markets quality products that effectively treat medical conditions and can help improve people's quality of life.